An open-label study evaluating the safety and efficacy of budesonide in patients with IgA nephropathy at high risk of progression.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
17 Nov 2023
17 Nov 2023
Historique:
received:
10
07
2023
accepted:
13
11
2023
medline:
27
11
2023
pubmed:
18
11
2023
entrez:
18
11
2023
Statut:
epublish
Résumé
We sought to evaluate the efficacy and safety of budesonide (Budenofalk) in the treatment of patients with IgA Nephropathy. We conducted a prospective, interventional, open-label, single-arm, non-randomized study that enrolled 32 patients with IgAN at high risk of progression (BUDIGAN study, ISRCTN47722295, date of registration 14/02/2020). Patients were treated with Budesonide at a dose of 9 mg/day for 12 months, subsequently tapered to 3 mg/day for another 12 months. The primary endpoints were change of eGFR and proteinuria at 12, 24 and 36 months. The study cohort had a mean eGFR and 24-h proteinuria of 59 ± 24 ml/min/1.73m
Identifiants
pubmed: 37978255
doi: 10.1038/s41598-023-47393-1
pii: 10.1038/s41598-023-47393-1
pmc: PMC10656480
doi:
Substances chimiques
Budesonide
51333-22-3
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
20119Informations de copyright
© 2023. The Author(s).
Références
Semin Nephrol. 2008 Jan;28(1):27-37
pubmed: 18222344
Kidney Int. 2018 Oct;94(4):674-681
pubmed: 29804660
Kidney Int. 2020 Oct;98(4):1044-1052
pubmed: 32450154
Am J Kidney Dis. 2016 Sep;68(3):392-401
pubmed: 27032886
Aliment Pharmacol Ther. 2020 Mar;51(6):644-651
pubmed: 32003028
JAMA. 2017 Aug 1;318(5):432-442
pubmed: 28763548
Clin J Am Soc Nephrol. 2023 Jun 1;18(6):727-738
pubmed: 37055195
Kidney Int. 2015 Nov;88(5):974-89
pubmed: 26376134
Kidney Int. 2013 Sep;84(3):622-3
pubmed: 23989362
J Am Soc Nephrol. 2023 Sep 29;:
pubmed: 37772889
Lancet. 2017 May 27;389(10084):2117-2127
pubmed: 28363480
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481
pubmed: 30635299
Kidney Int. 2023 Feb;103(2):391-402
pubmed: 36270561
PLoS One. 2019 Aug 9;14(8):e0221014
pubmed: 31398224
Clin J Am Soc Nephrol. 2018 Oct 8;13(10):1584-1586
pubmed: 30065067
Kidney Int. 2023 Feb;103(2):258-261
pubmed: 36681455
Nephrol Ther. 2018 Apr;14 Suppl 1:S13-S21
pubmed: 29606258
Nephrol Dial Transplant. 2020 Aug 1;35(8):1291-1294
pubmed: 31860097
Medicine (Baltimore). 2020 Jun 26;99(26):e21000
pubmed: 32590815
Am J Kidney Dis. 2020 Jan;75(1):84-104
pubmed: 31473020
J Clin Med. 2019 Oct 02;8(10):
pubmed: 31581654
J Gastroenterol Hepatol. 2018 Mar 30;:
pubmed: 29603368
Clin Exp Nephrol. 2019 May;23(5):577-588
pubmed: 30756248
Ren Fail. 2010 May;32(4):523-7
pubmed: 20446796
Kidney Int. 2021 Jul;100(1):215-224
pubmed: 33878338
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
Semin Nephrol. 2018 Sep;38(5):504-512
pubmed: 30177022
Nephrol Dial Transplant. 2011 Oct;26(10):3237-42
pubmed: 21378156
Expert Rev Clin Immunol. 2011 Jul;7(4):419-28
pubmed: 21790284
Kidney Int. 2017 May;91(5):1014-1021
pubmed: 28341274
Clin J Am Soc Nephrol. 2014 Feb;9(2):265-70
pubmed: 24262508
PLoS One. 2019 Feb 22;14(2):e0212254
pubmed: 30794576
Nephrol Dial Transplant. 2018 Apr 1;33(4):661-669
pubmed: 29106637
JAMA. 2022 May 17;327(19):1888-1898
pubmed: 35579642
Clin J Am Soc Nephrol. 2019 Oct 7;14(10):1458-1465
pubmed: 31511226
Kidney Int. 2021 Oct;100(4S):S1-S276
pubmed: 34556256
Kidney Int. 2012 Oct;82(7):790-6
pubmed: 22673888
N Engl J Med. 2015 Dec 3;373(23):2225-36
pubmed: 26630142